Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 202

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 202
---
 30,Nine Months EndedSeptember 30,2025202420252024Numerator:   Net income (loss)$5,432 $(143,466)$5,397 $(115,601)Denominator:   Weighted average common shares outstanding—basic44,038 46,134 45,257 46,269 Computation of diluted securities:   Dilutive effect of stock options37 — 32—    Dilutive effect of RSUs383 — 429 — Dilutive effect of ESPP share options1 — 11 —    Weighted average common shares outstanding—diluted44,459 46,134 45,729 46,269 Net income (loss) per common share:   Basic and diluted net income (loss) per common share$0.12 $(3.11)$0.12 $(2.50)

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  28

The following table summarizes the outstanding stock options, RSUs, ESPP share options and convertible senior notes that were excluded from the diluted net income (loss) per common share calculation because the effects of including these potential shares were antidilutive in the periods presented (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Weighted average number of stock options6,488 6,925 6,573 7,305 2025 Notes972 2,821 2,205 4,184 Weighted average number of RSUs1,531 2,637 1,831 1,935 Weighted average ESPP share options— 47 — 51       Total8,991 12,430 10,609 13,475 

NOTE 14—INCOME TAXES

Income (loss) before income taxes and income tax expense are as follows (dollar amounts in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Income (loss) before income taxes:   Domestic$10,497 $(140,309)$16,956 $(89,656)   Foreign(973)1,453 (653)1,024 Total income (loss) before income taxes$9,524 $(138,856)$